The Agaricus blazei-based mushroom extract, AndosanTM, has immuno-suppressive and anti-inflammatory effects when used as supplement to multiple myeloma patients receiving high-dose chemotherapy and autologous bone marrow transplantation
-
1
Oslo University Hospital, Norway
Agaricus blazei Murill (AbM) is an edible Brazilian Basidiomycetes mushroom used in traditional medicine against cancer, which has antitumor effects against myeloma and other cancers in mouse models. Ahn et al 2004 (1), reported increased NK cell activity and life quality in patients with gynecological cancer who received AbM extract as supplement to high-dose chemotherapy. We found (2) anti-inflammatory effects in inflammatory bowel disease patients who took oral supplement for 2 weeks of the AbM-based extract, AndosanTM, also containing the related medicinal mushrooms; Hericium erinaceous (15%) and Grifola frondosa (3%). In vitro AndosanTM activated human monocyte-derived dendritic cells (3) and increased proliferation of normal CD56+ hematopoietic stem cells. A placebo-controlled, double-blinded study in 33 multiple myeloma patients who drank 60 ml/day of AndosanTM for 7 weeks as supplement to high dose chemotherapy with autologous stem cell support, showed these immunological findings:
In the AndosanTM relative to placebo group there were increased Treg cells (CD4+, CD127d + CD25+) in the apheresis product harvested for bone marrow transplantation after 2 weeks treatment, and increased plasma levels after 7 weeks in IL-1 receptor antagonist, IL-5 and IL-7 cytokines and up-regulation of immune function-related genes in the bone marrow. This shows that the AbM-based mushroom extract, AndosanTM, may have clinically significant immuno-suppressive and anti-inflammatory effects in multiple myeloma patients when used as supplement to high-dose chemotherapy with autologous bone marrow transplantation. The T reg cell increase is probably influenced by enhanced IL-7, a modulator of T cell development. There was no difference in circulating lymphocytes between the patient groups. Clinical status and survival rates are being supervised.
Acknowledgements
Sponsors: Oslo University Hospital and Immunopharma, Norway,
References
1) Ahn WS, Kim DJ, Chae GT, Lee JM, Bae SM, Sin JI, Kim YW, Namkoong SE, Lee IP. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer. 2004;14(4):589-94.
2) Førland DT, Johnson E, Saetre L, Lyberg T, Lygren I, Hetland G. Effect of an extract based on the medicinal mushroom Agaricus blazei Murill on expression of cytokines and calprotectin in patients with ulcerative colitis and Crohn's disease. Scand J Immunol. 2011;73(1):66-75.
3) Førland DT, Johnson E, Tryggestad AM, Lyberg T, Hetland G. An extract based on the medicinal mushroom Agaricus blazei Murill stimulates monocyte-derived dendritic cells to cytokine and chemokine production in vitro. Cytokine. 2010;49(3):245-50.
Keywords:
Agaricus blazei,
AndosanTM,
medicinal mushroom,
Multiple Myeloma,
immune suppression,
Anti-Inflammatory Agents
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Translational immunology and immune intervention
Citation:
Hetland
G,
Tangen
J,
Tierens
A,
Kvalheim
G,
Osnes
LT and
Tjonnfjord
GE
(2013). The Agaricus blazei-based mushroom extract, AndosanTM, has immuno-suppressive and anti-inflammatory effects when used as supplement to multiple myeloma patients receiving high-dose chemotherapy and autologous bone marrow transplantation.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00740
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
18 Jun 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Dr. Geir Hetland, Oslo University Hospital, Oslo, Norway, geir.hetland@ous-hf.no